What do systematic reviews say?

NB‐UVB vs medium‐dose UVA‐1 phototherapy (50 J/cm²)

• Interventions for morphea 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Low

NB‐UVB vs low‐dose UVA‐1 phototherapy (20 J/cm²)

• Interventions for morphea 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Very low

Medium‐dose UVA‐1 phototherapy (50 J/cm²) vs low‐dose UVA‐1 phototherapy (20 J/cm²)

• Interventions for morphea 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Low

Moxifloxacin vs amoxicillin‐clavulanate

It is very uncertain whether moxifloxacin changes mortality compared with amoxicillin‐clavulanate (very low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 3 [0.39, 23.07]
  1 study · 54 participants
  Very low

IVIg vs placebo

Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 0.73 [0.32, 1.65]
  1 study · 100 participants
  Low

IVIg vs placebo

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Low

IVIg vs placebo

The review found no eligible studies for this question.

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Moxifloxacin vs amoxicillin‐clavulanate

It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 0.63 [0.3, 1.31]
  1 study · 54 participants
  Very low

Moxifloxacin vs amoxicillin‐clavulanate

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 54 participants
  Very low

Moxifloxacin vs amoxicillin‐clavulanate

The review found no eligible studies for this question.

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

AB103 vs placebo

It is very uncertain whether AB103 changes mortality compared with placebo (very low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 0.34 [0.05, 2.16]
  1 study · 43 participants
  Very low

AB103 vs placebo

It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 1.49 [0.52, 4.27]
  1 study · 43 participants
  Very low

AB103 vs placebo

The review found no eligible studies for this question.

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

AB103 vs placebo

The review found no eligible studies for this question.

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

IVIg vs placebo

Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 1.17 [0.42, 3.23]
  1 study · 100 participants
  Low